Skip to main content

What the FDA labels say about taking them together

Dabrafenib and trametinib

Dabrafenib's FDA label of May 20, 2026 names trametinib in its warnings and precautions section, and trametinib's label names dabrafenib too. The trametinib label: “Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.”

Check it at the source: the dabrafenib FDA label on DailyMed (effective May 20, 2026, Novartis Pharmaceuticals Corporation); the trametinib FDA label on DailyMed (effective May 7, 2026, Novartis Pharmaceuticals Corporation).

What does the dabrafenib label say about trametinib?

Dabrafenib label, warnings and precautions

WARNINGS AND PRECAUTIONS New Primary Malignancies, Cutaneous and Non-Cutaneous: Can occur when TAFINLAR is administered as a single agent or with trametinib.

Source: FDA drug label (Tafinlar), Novartis Pharmaceuticals Corporation, effective May 20, 2026 (SPL set fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea), via openFDA; the full label on DailyMed

What does the trametinib label say about dabrafenib?

Trametinib label, drug interactions

Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.

Trametinib label, warnings and precautions

WARNINGS AND PRECAUTIONS New Primary Malignancies, Cutaneous and Non-Cutaneous: Can occur when MEKINIST is used with dabrafenib.

Source: FDA drug label (Mekinist), Novartis Pharmaceuticals Corporation, effective May 7, 2026 (SPL set 0002ad27-779d-42ab-83b5-bc65453412a1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Dabrafenib generic labelers
0Trametinib generic labelers
DabrafenibTrametinib
Labeled forLung cancerLung cancer
Boxed warningNoNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?